Search - tctmd.com

Displaying 501 - 520 of 1142

Sort: Relevancy | Date

Presentation TCT 2018

TCT-15: Two-Year Outcomes After Transcatheter Aortic Valve Replacement With Mechanically- versus Self-Expandable Valves: Results From The REPRISE III Randomized Trial

Presenter: Charles J. Davidson, Jeffrey J. Popma, Michael J. Reardon

September 21, 2018

Presentation TCT 2018

TCT-18: Novel Concept Of Catheter-Based Treatment For Tricuspid Regurgitation (Cerclage-TR Block): A Preliminary Animal Experiment in a Swine Model

Presenter: Eric Eeckhout, Glenn Van Langenhove, Min-Ku Chon

September 21, 2018

Presentation TCT 2018

TCT-14: Final 5-Year Outcomes Of The REPRISE II Study: Long-Term Outcomes With the Fully Repositionable and Retrievable Lotus Transcatheter Aortic Valve

Presenter: Charles J. Davidson, Jeffrey J. Popma, Nicolas Dumontiel

September 21, 2018

Presentation TCT 2018

Update of the NeoVas BRS Clinical Trials

Presenter: Runlin Gao, Martin B. Leon, Yaling Han

September 21, 2018

Presentation TCT 2018

The Endpoints for Translational Mitral/Tricuspid Valve Development

Presenter: Robert O. Bonow, John C Laschinger, Blase A. Carabello

September 21, 2018

Presentation TCT 2018

TCT-17: Tricuspid Valve Regurgitation Reduction Following Concomitant Subvalvular and Annulus-Level Treatment Ex-Vivo Study

Presenter: Eric Eeckhout, Glenn Van Langenhove, Michal Jaworek

September 21, 2018

Presentation TCT 2018

New TAVR Devices: VitaFlow, Venus A Plus, and Venibri

Presenter: Runlin Gao, Martin B. Leon, Junbo Ge

September 21, 2018

Presentation TCT 2018

The Methods for Translational Mitral/Tricuspid Valve Development

Presenter: Robert O. Bonow, John C Laschinger, Michael J. Mack

September 21, 2018

Presentation TCT 2018

Debate Con: TAVR for Moderate-Risk Patients: SAVR Remains First Line of Therapy!

Presenter: Jose Armando Mangione

September 21, 2018

Presentation TCT 2018

Debate Pro: TAVR for Moderate-Risk Patients: Ready for Prime Time!

Presenter: Gerardo Nau

September 21, 2018

Presentation TCT 2018

TAVR in the Patient With Atrial Fibrillation and Contraindications to Chronic Anticoagulation

Presenter: Anibal A. Damonte

September 21, 2018

Presentation TCT 2018

The Endpoints for Aortic Valve Development

Presenter: Jeroen J. Bax, Martin B. Leon, Ori Ben-Yehuda

September 21, 2018

Presentation TCT 2018

Mitra Clip in the Spotlight: What Should We Proceed After the MITRA-FR Trial?

Presenter: Marco Alcantara

September 21, 2018

Presentation TCT 2018

Interventional Pathobiology: Understanding Pathology and Device Interaction

Presenter: Juan F. Granada

September 21, 2018

Presentation TCT 2018

Mitral Valvular Heart Disease: Diagnosis and Treatment Options 2018

Presenter: Joseph P. Carrozza Jr, Jose M. Wiley, Ramon Quesada

September 21, 2018

Presentation TCT 2018

Interventional Innovation Highlights: Stent Retriever Embolectomy in Primary PCI With High Thrombotic Burden

Presenter: Carlos E. Uribe

September 21, 2018

Presentation TCT 2018

Interventional Management of Cardiogenic Shock: Clinical Indications and Therapeutic Options

Presenter: William W. O'Neill

September 21, 2018

Presentation TCT 2018

Aortic Valvular Heart Disease: Diagnosis and Treatment Options 2018

Presenter: Joseph P. Carrozza Jr, Jose M. Wiley, Nicola Corvaja

September 21, 2018

Presentation TCT 2018

Primary PCI and Multivessel Disease: Regional Insights and Variations

Presenter: Roberto Botelho

September 21, 2018

Presentation TCT 2018

Vascular Access in Primary PCI: The Always Radial Approach?

Presenter: Luis Perez

September 21, 2018

Advertisement

TCT-15: Two-Year Outcomes After Transcatheter Aortic Valve Replacement With Mechanically- versus Self-Expandable Valves: Results From The REPRISE III Randomized Trial

TCT-18: Novel Concept Of Catheter-Based Treatment For Tricuspid Regurgitation (Cerclage-TR Block): A Preliminary Animal Experiment in a Swine Model

TCT-14: Final 5-Year Outcomes Of The REPRISE II Study: Long-Term Outcomes With the Fully Repositionable and Retrievable Lotus Transcatheter Aortic Valve

Update of the NeoVas BRS Clinical Trials

The Endpoints for Translational Mitral/Tricuspid Valve Development

TCT-17: Tricuspid Valve Regurgitation Reduction Following Concomitant Subvalvular and Annulus-Level Treatment Ex-Vivo Study

New TAVR Devices: VitaFlow, Venus A Plus, and Venibri

The Methods for Translational Mitral/Tricuspid Valve Development

Debate Con: TAVR for Moderate-Risk Patients: SAVR Remains First Line of Therapy!

Debate Pro: TAVR for Moderate-Risk Patients: Ready for Prime Time!

TAVR in the Patient With Atrial Fibrillation and Contraindications to Chronic Anticoagulation

The Endpoints for Aortic Valve Development

Mitra Clip in the Spotlight: What Should We Proceed After the MITRA-FR Trial?

Interventional Pathobiology: Understanding Pathology and Device Interaction

Mitral Valvular Heart Disease: Diagnosis and Treatment Options 2018

Interventional Innovation Highlights: Stent Retriever Embolectomy in Primary PCI With High Thrombotic Burden

Interventional Management of Cardiogenic Shock: Clinical Indications and Therapeutic Options

Aortic Valvular Heart Disease: Diagnosis and Treatment Options 2018

Primary PCI and Multivessel Disease: Regional Insights and Variations

Vascular Access in Primary PCI: The Always Radial Approach?

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content